TABLE 3

DMPP resistance and developmental speed in animals with tissue-specific daf-16 expression

Genotype% daueraDMPPR (no. of animals, experiments)bL2 duration in hr (no. of lines scored)d
daf-2(e1370)90.2 ± 7.294 ± 2 (643, 9)20
daf-16(mu86); daf-2(e1370)0.1 ± 0.62 ± 1 (793, 9)10
daf-16(mu86); daf-2(e1370); krEx841-843[rol-6(gf)]017 ± 8 (634, 12)13 (3)
daf-16(mu86); daf-2(e1370); muEx176[Pdaf-16∷gfp∷daf-16]35.1100 ± 13c (118, 5)30 (1)
daf-16(mu86); daf-2(e1370); muEx169[Punc-119∷gfp∷daf-16]6334 ± 8 (196, 10)15 (1)
daf-16(mu86); daf-2(e1370); muEx211[Pges-1∷gfp∷daf-16]045 ± 8c (188, 6)ND
daf-16(mu86); daf-2(e1370); muEx212[Pmyo-3∷gfp∷daf-16]037 ± 5c (213, 6)15 (1)
  • daf-16 tissue-specific rescue lines are described in Libina et al. (2003). Three independent rol-6(gf) lines were generated as a control by injecting pRF4 at 100 ng/μL, together with L3570 (Pmyo-3∷GFP) at 10 ng/μL.

  • a Dauer formation at 25.5° as reported in Libina et al. (2003). In rol-6(gf) control lines, dauer formation was scored at 25.5° (three lines, six experiments, 535 total individuals).

  • b Percentage of survival on 0.75 mm DMPP at 20° (average ± SEM).

  • c P ≤ 0.05 when compared to the rol-6(gf) co-injection controls (Student's t-test).

  • d L2 stage duration was determined at 20°. ND, not determined.